MCID: LCR008
MIFTS: 44

Lacrimal Apparatus Disease

Categories: Eye diseases

Aliases & Classifications for Lacrimal Apparatus Disease

MalaCards integrated aliases for Lacrimal Apparatus Disease:

Name: Lacrimal Apparatus Disease 12 15
Lacrimal Apparatus Diseases 73

Classifications:



External Ids:

Disease Ontology 12 DOID:1400
ICD10 33 H04 H04.9
ICD9CM 35 375 375.9
MeSH 44 D007766
NCIt 50 C26809
UMLS 73 C0022904

Summaries for Lacrimal Apparatus Disease

MalaCards based summary : Lacrimal Apparatus Disease, also known as lacrimal apparatus diseases, is related to excessive tearing and scorpion envenomation, and has symptoms including eye manifestations, dacryops and visual disturbance. An important gene associated with Lacrimal Apparatus Disease is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are NF-KappaB Family Pathway and Th17 cell differentiation. The drugs Hyaluronic acid and Calcium Carbonate have been mentioned in the context of this disorder. Affiliated tissues include eye, salivary gland and b cells, and related phenotypes are digestive/alimentary and immune system

Related Diseases for Lacrimal Apparatus Disease

Diseases related to Lacrimal Apparatus Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 195)
# Related Disease Score Top Affiliating Genes
1 excessive tearing 11.3
2 scorpion envenomation 10.9 IL6 TNF
3 systemic onset juvenile idiopathic arthritis 10.9 IL1B TNF
4 punctate inner choroidopathy 10.9 IL10 TNF
5 staphylococcal toxic shock syndrome 10.8 IL1B TNF
6 leukomalacia 10.8 IL6 TNF
7 recurrent corneal erosion 10.8 IL1B IL6
8 dental pulp disease 10.8 IL1B TNF TRPV1
9 subacute cutaneous lupus erythematosus 10.8 TNF TRIM21
10 tropical endomyocardial fibrosis 10.8 IL10 TNF
11 angioimmunoblastic lymphadenopathy with dysproteinemia 10.8 IL6 TNF
12 autoimmune myocarditis 10.8 IL1B TNF
13 bagassosis 10.8 IL1B IL6
14 burning mouth syndrome 10.8 IL6 TNF TRPV1
15 rosacea 10.8 IL6 TNF TRPV1
16 laryngitis 10.8 IL1B IL6 TNF
17 acute vascular insufficiency of intestine 10.8 IL1B IL6 TNF
18 poems syndrome 10.8 IL1B IL6 TNF
19 osteosclerotic myeloma 10.8 IL1B IL6 TNF
20 stachybotrys chartarum 10.8 IL1B IL6 TNF
21 pancreas disease 10.7 IL6 TNF TRPV1
22 endometritis 10.7 IL1B IL6 TNF
23 joint disorders 10.7 IL1B IL6 TNF
24 commensal bacterial infectious disease 10.7 IL1B IL6 TNF
25 adult-onset still's disease 10.7 IL1B IL6 TNF
26 dengue shock syndrome 10.7 IL1B IL6 TNF
27 chikungunya 10.7 IL1B IL6 TNF
28 acute respiratory distress syndrome 10.7 IL1B IL6 TNF
29 kashin-beck disease 10.7 IL1B TNF
30 bacterial vaginosis 10.7 IL1B IL6 TNF
31 pericarditis 10.7 IL1B IL6 TNF
32 placenta disease 10.7 IL1B IL6 TLR9
33 typhoid fever 10.7 IL1B IL6 TNF
34 periodontitis, chronic 10.7 IL1B IL6
35 mucocutaneous leishmaniasis 10.7 IL10 TLR9 TNF
36 hyperglobulinemic purpura 10.7 HSPG2 TRIM21
37 esophagitis 10.7 IL1B IL6 TRPV1
38 chorioamnionitis 10.7 IL1B IL6 TNF
39 lyme disease 10.7 IL1B IL6 TNF
40 cystitis 10.7 IL6 TNF TRPV1
41 nasal cavity disease 10.7 IL10 TLR9 TRPV1
42 coccidiosis 10.7 IL10 TLR9 TNF
43 pneumoconiosis 10.7 IL1B IL6 TNF
44 critical limb ischemia 10.7 IL6 TNF
45 microscopic polyangiitis 10.6 IL10 TNF
46 gingivitis 10.6 IL1B IL6 TNF
47 overnutrition 10.6 IL6 TNF TRPV1
48 eye lymphoma 10.6 IL10 IL6 TLR9
49 multifocal choroiditis 10.6 IL10 TNF
50 aseptic meningitis 10.6 IL10 IL1B TNF

Graphical network of the top 20 diseases related to Lacrimal Apparatus Disease:



Diseases related to Lacrimal Apparatus Disease

Symptoms & Phenotypes for Lacrimal Apparatus Disease

UMLS symptoms related to Lacrimal Apparatus Disease:


eye manifestations, dacryops, visual disturbance

MGI Mouse Phenotypes related to Lacrimal Apparatus Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.76 IL10 IL6 MUC5AC PPP1R12A TLR9 TNF
2 immune system MP:0005387 9.73 IL10 IL1B IL6 MUC5AC PPP1R12A TLR9
3 integument MP:0010771 9.23 HSPG2 IL10 IL1B IL6 TNF TRIM21

Drugs & Therapeutics for Lacrimal Apparatus Disease

Drugs for Lacrimal Apparatus Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 275)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 9004-61-9 53477741
2
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
3
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
5
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
6
Povidone Approved Phase 4,Not Applicable 9003-39-8
7
Loteprednol Approved Phase 4,Phase 3,Phase 2,Not Applicable 82034-46-6, 129260-79-3 444025 9865442
8
Glycerol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 56-81-5 753
9
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 299-42-3 9294
10
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 90-82-4 7028
11
Menthol Approved Phase 4,Phase 2,Not Applicable 2216-51-5 16666
12
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6 23994
13
Azithromycin Approved Phase 4 83905-01-5 55185 447043
14
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
15
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
16
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
17
Dipivefrin Approved Phase 4,Phase 3 52365-63-6 3105
18
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
19
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
20
Ofloxacin Approved Phase 4 82419-36-1 4583
21
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
22
Tacrolimus Approved, Investigational Phase 4,Not Applicable 104987-11-3 445643 439492
23
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
24
Pilocarpine Approved, Investigational Phase 4 54-71-7, 92-13-7 5910
25
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 564-25-0 54671203
26
Dimenhydrinate Approved Phase 4,Not Applicable 523-87-5 441281
27
Sorbitol Approved Phase 4 50-70-4 5780
28
Tocopherol Approved, Investigational, Nutraceutical Phase 4,Not Applicable 1406-66-2 14986
29
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
30
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 1406-16-2
31
Vitamin D3 Approved, Nutraceutical Phase 4,Not Applicable 67-97-0 6221 5280795
32
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 59-02-9 14985
33
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 4,Phase 2 53-43-0 9860744
34
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Not Applicable 8001-79-4
35
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538 444795
36 Gallopamil Investigational Phase 4 16662-47-8
37
Bromfenac Approved July 1997 Phase 4,Phase 3,Phase 2 91714-94-2 60726
38 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Not Applicable
39 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Tetrahydrozoline Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Viscosupplements Phase 4,Phase 3,Phase 2,Not Applicable
43 Antacids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 597)
# Name Status NCT ID Phase Drugs
1 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
2 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
3 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
4 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
5 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
6 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
7 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
8 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
9 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4 dehydroepiandrosterone
10 The Safety and Efficacy of Lacrimal Silicone Intubation for the Management of Epiphora Completed NCT01010659 Phase 4
11 Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed NCT00407043 Phase 4 Lotemax;Restasis
12 A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Completed NCT02139033 Phase 4 Retaine™
13 Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms Completed NCT03451396 Phase 4 Lifitegrast
14 The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED Completed NCT02120079 Phase 4 Lotemax;Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)
15 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
16 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Completed NCT01014078 Phase 4 Azithromycin Ophthalmic Solution, 1%;Placebo
17 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
18 Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease Completed NCT00567177 Phase 4 Restasis, Refresh Plus
19 Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase Completed NCT00520260 Phase 4 bromfenac;ketorolac
20 Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops Completed NCT02758327 Phase 4 TheraTears Lubricating Eye Drops
21 Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis® Completed NCT02554981 Phase 4 Cyclosporine 0.05% Ophthalmic Emulsion
22 Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy Completed NCT02121847 Phase 4 cyclosporine 0.05% ophthalmic emulsion;carboxymethylcellulose-based lubricant eye drops
23 Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects Completed NCT01970917 Phase 4
24 The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients Completed NCT01280110 Phase 4 Hydroxypropylmethylcellulose;Carboxymethylcellulose
25 Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Completed NCT01198782 Phase 4
26 Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery Completed NCT00909324 Phase 4 Pre-LASIK 0.3% hypromellose;Post-LASIK 0.3% hypromellose
27 Systane Clinical Experience Study Completed NCT00818909 Phase 4
28 Efficacy and Acceptability of Two Lubricant Eye Drops Completed NCT00756678 Phase 4 Lubricant Eye Drops (Optive™);Lubricating Eye Drops (blink® Tears)
29 Refractive Surgery and Optive Compatibility Study Completed NCT00469157 Phase 4 Optive
30 Soothe Versus Refresh Completed NCT00284999 Phase 4 Soothe;Refresh Tears
31 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
32 Quality of Life and Sjögren Syndrome Completed NCT03578900 Phase 4 Xeros;Citric Acid based Mouthwash
33 Comparative Study of Rohto Dry-Aid® and Systane® Ultra in Patients With Dry Eye Completed NCT03183089 Phase 4 Rohto Dry-Aid®;Systane® Ultra
34 Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra) Completed NCT02985827 Phase 4 Rohto (r) Hydra;Systane (r) Ultra
35 A Study of the Effect of Zinc-Hyaluronate on Ocular Surface Sensations in Patients With Dry Eye Completed NCT02951910 Phase 4
36 Comparison of Autologous Serum Versus Preservative Free Artificial Tear Completed NCT02752763 Phase 4 %40 diluted Autologous serum;Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)
37 Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome Completed NCT02585453 Phase 4
38 A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study Completed NCT02049112 Phase 4
39 A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms Completed NCT02028754 Phase 4 Sodium Carboxymethylcellulose;Levofloxacin;Prednisolone
40 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products (DUNLIN) Completed NCT02014922 Phase 4 TheraTears® Lubricant Eye Drop;TheraTears® preservative-free single-use containers
41 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease Completed NCT02004067 Phase 4 Restasis;Refresh Endura
42 Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome Completed NCT01864330 Phase 4
43 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
44 Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz Completed NCT01742884 Phase 4
45 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Completed NCT01684436 Phase 4
46 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients Completed NCT01682460 Phase 4 Refresh Tears Lubricant Eye Drops (Allergan)
47 Efficacy Study of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints Completed NCT01543061 Phase 4
48 The Effect of Ocular Lubricant Eyedrops on Lid Parallel Conjunctival Folds and Other Signs and Symptoms of Dry Eye Completed NCT01268735 Phase 4 Lubricating eyedrops containing hydroxypropyl-guar
49 Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye Completed NCT01105910 Phase 4
50 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE) Completed NCT01105624 Phase 4 azithromycin ophthalmic solution, 1%;Visine® for Contacts®

Search NIH Clinical Center for Lacrimal Apparatus Disease

Genetic Tests for Lacrimal Apparatus Disease

Anatomical Context for Lacrimal Apparatus Disease

MalaCards organs/tissues related to Lacrimal Apparatus Disease:

41
Eye, Salivary Gland, B Cells, Thyroid, Testes, Neutrophil, Skin

Publications for Lacrimal Apparatus Disease

Variations for Lacrimal Apparatus Disease

Expression for Lacrimal Apparatus Disease

Search GEO for disease gene expression data for Lacrimal Apparatus Disease.

Pathways for Lacrimal Apparatus Disease

Pathways related to Lacrimal Apparatus Disease according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.61 AREG IL1B IL6 TLR9 TNF
2
Show member pathways
12.36 IL10 IL1B IL6 TNF
3
Show member pathways
12.33 IL10 IL1B IL6 TNF
4
Show member pathways
12.24 IL1B IL6 MUC5AC TNF
5
Show member pathways
12.15 IL10 IL1B IL6 TLR9 TNF
6
Show member pathways
12.12 IL1B IL6 MUC5AC TNF
7 12.11 IL10 IL1B IL6 TLR9 TNF
8
Show member pathways
12.09 IL1B IL6 TLR9 TNF
9 12.07 IL10 IL1B IL6 TNF
10
Show member pathways
12.07 IL10 IL1B IL6 TLR9 TNF
11 11.88 IL10 IL1B IL6 TNF
12 11.81 IL1B IL6 TNF
13 11.8 IL1B IL6 TNF
14 11.79 IL10 IL1B IL6 TNF
15 11.76 IL1B IL6 TNF
16 11.7 IL10 IL1B TNF
17 11.68 IL10 IL1B IL6 TNF
18 11.58 IL1B IL6 TNF
19
Show member pathways
11.57 IL1B IL6 TNF
20 11.5 IL1B IL6 TNF
21 11.42 IL10 IL1B IL6 TLR9 TNF
22 11.4 IL10 IL1B IL6 TNF
23 11.38 IL1B IL6 TNF
24 11.21 IL10 IL1B IL6 TNF
25 11.2 IL1B IL6 TNF
26 11.13 AREG IL1B IL6 TNF
27 11.04 IL10 IL1B IL6 TLR9 TNF
28 11.03 IL10 IL1B IL6 TNF
29 10.57 IL10 IL1B IL6 TLR9 TNF

GO Terms for Lacrimal Apparatus Disease

Cellular components related to Lacrimal Apparatus Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 AREG HSPG2 IL10 IL1B IL6 LACRT
2 extracellular region GO:0005576 9.44 BPIFA2 CDSN DNASE1L1 HSPG2 IL10 IL1B

Biological processes related to Lacrimal Apparatus Disease according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.93 AREG IL10 IL1B IL6 LACRT TNF
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.84 IL1B IL6 TLR9 TNF
3 defense response to bacterium GO:0042742 9.83 BPIFA2 IL10 LACRT TLR9 TNF
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.81 AREG IL6 LACRT
5 positive regulation of JNK cascade GO:0046330 9.8 IL1B TLR9 TNF
6 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.76 IL1B TLR9 TNF
7 positive regulation of nitric oxide biosynthetic process GO:0045429 9.73 IL1B TNF TRPV1
8 positive regulation of interleukin-8 production GO:0032757 9.67 IL1B TLR9 TNF
9 response to glucocorticoid GO:0051384 9.67 AREG IL10 IL6 TNF
10 negative regulation of growth of symbiont in host GO:0044130 9.65 IL10 TNF
11 negative regulation of interleukin-6 production GO:0032715 9.65 IL10 TLR9 TNF
12 positive regulation of calcineurin-NFAT signaling cascade GO:0070886 9.64 LACRT TNF
13 response to molecule of bacterial origin GO:0002237 9.64 IL10 TLR9
14 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.63 IL1B TLR9
15 negative regulation of lipid storage GO:0010888 9.62 IL6 TNF
16 positive regulation of chemokine biosynthetic process GO:0045080 9.61 IL1B TNF
17 endothelial cell apoptotic process GO:0072577 9.61 IL10 TNF
18 negative regulation of cytokine secretion involved in immune response GO:0002740 9.6 IL10 TNF
19 negative regulation of interleukin-8 production GO:0032717 9.59 IL10 TLR9
20 positive regulation of fever generation GO:0031622 9.58 IL1B TNF
21 positive regulation of chemokine production GO:0032722 9.58 IL6 TLR9 TNF
22 fever generation GO:0001660 9.57 IL1B TRPV1
23 positive regulation of interleukin-6 production GO:0032755 9.56 IL1B IL6 TLR9 TNF
24 sequestering of triglyceride GO:0030730 9.55 IL1B TNF
25 positive regulation of DNA binding transcription factor activity GO:0051091 9.55 IL10 IL1B IL6 TNF TRIM21
26 receptor biosynthetic process GO:0032800 9.52 IL10 TNF
27 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.51 IL1B TNF
28 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.5 IL10 IL1B TNF
29 inflammatory response GO:0006954 9.17 HSPG2 IL10 IL1B IL6 TLR9 TNF
30 regulation of establishment of endothelial barrier GO:1903140 9.13 IL1B PPP1R12A TNF

Molecular functions related to Lacrimal Apparatus Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 AREG IL10 IL6 LACRT
2 cytokine activity GO:0005125 9.02 AREG IL10 IL1B IL6 TNF

Sources for Lacrimal Apparatus Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....